Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans (MPG1)

Phase 2 open-label study testing two once-monthly MDMA-assisted group therapy sessions (120 mg initial with optional 60 mg supplemental 1.5–2 hours later) combined with preparatory and integrative non-drug therapy in veterans with moderate or greater PTSD.

Primary outcome is change in CAPS-5 assessed by a blinded independent rater pool; feasibility and safety assessed through adverse events, vitals, and study retention across three cohorts.